A full breakdown of the innovative drug supply chain: the underlying logic has completely changed!
CRO (R&D outsourcing): handles R&D from 0 to 1, kind of like the data-labeling plus model-training service providers in AI. In the early stage, finding targets, running animal experiments, and conducting clinical trials — most of this dirty, heavy work gets done by CROs for the drug companies. The leaders in preclinical CRO are WuXi AppTec and Pharmaron; the absolute leader in clinical-stage CRO is Tigermed, plus niche leaders like Joinn Laboratories that focus on safety assessment.
CDMO (contract manufacturing): handles mass production from 1 to N, kind of like TSMC in the chip industry. Once a drug company designs a drug, building its own production line is too costly and risky, so it hands manufacturing to CDMO companies. Ordinary small-molecule CDMO has a relatively low technical barrier — Asymchem, Porton Pharma Solutions, and Jiuzhou Pharma are the core leaders. But for cutting-edge biologics like ADC and CGT, the CDMO technical barrier is absurdly high — over 90% of drug companies simply can't build their own production lines, outsourcing rates are close to 100%, and unit prices are 3-5x those of ordinary drugs. That makes it the most elastic upstream segment in this rally. For example, WuXi XDC, which specializes in ADC CDMO, and VectorBuilder, which does CGT CDMO, have both far outpaced ordinary CXO in this run.
In this round, ordinary CXO rose steadily but with limited elasticity, while specialty CDMOs tied to ADC and CGT saw both volume and price rise together — the golden track within the upstream.
Second part: core raw materials and molecular building blocks
A lot of people only stare at the midstream drug companies and overlook the most bottlenecked upstream raw material segment. Just as making chips is impossible without photoresist and silicon wafers, making innovative drugs is impossible without key raw materials — especially for high-end drugs like ADC, where the technical barrier on core raw materials can be even higher than on the finished drug.
ADC, commonly called a "biological missile," consists of three parts: the antibody for targeting, the linker that acts as a switch, and the toxin that serves as the warhead. The linker and toxin are the core chips that determine the missile's power and safety — the linker has to stay attached in the bloodstream and release precisely inside cancer cells, while the toxin has to be lethal enough with minimal side effects. This part used to be monopolized overseas for a long time, but domestic companies have now made breakthroughs.
Representative companies in this segment include PharmaBlock, which makes molecular building blocks and ADC linkers; Aarti Drugs, which makes high-potency toxin intermediates; and supporting players like Haoyuan Pharma and Apeloa. Once the ADC track took off, their orders doubled outright — a truly hardcore segment quietly making a fortune.
Third part: pharmaceutical equipment and lab consumables
You can't make drugs bare-handed — you need high-end equipment and core consumables, the "lithography machines plus servers" of biologics. Examples include bioreactors for culturing cells, drug lyophilizers, aseptic filling lines, and chromatography media, often called the "chips of biologics" — these used to be almost entirely imported, and now domestic substitution is accelerating.
Equipment leaders are Tofflon and Truking Technology, which can make everything from biologics production lines to specialized equipment for ADC and CGT. On the consumables side, the hardest-core player is NanoMicro Technology, whose chromatography media broke a decades-long overseas monopoly and is an indispensable core material in biologics purification. There's also Haofan Biology, which makes peptide synthesis reagents and ADC crosslinkers and ranks among the global market share leaders.
Comments
0